JPWO2019213610A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213610A5 JPWO2019213610A5 JP2020561821A JP2020561821A JPWO2019213610A5 JP WO2019213610 A5 JPWO2019213610 A5 JP WO2019213610A5 JP 2020561821 A JP2020561821 A JP 2020561821A JP 2020561821 A JP2020561821 A JP 2020561821A JP WO2019213610 A5 JPWO2019213610 A5 JP WO2019213610A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- cell according
- antigen
- apc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 24
- 238000000034 method Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 claims 4
- 101710121417 Envelope glycoprotein Proteins 0.000 claims 4
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 4
- 102100030704 Interleukin-21 Human genes 0.000 claims 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108010074108 interleukin-21 Proteins 0.000 claims 4
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 3
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 3
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 3
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 3
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 3
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 3
- 108700012411 TNFSF10 Proteins 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims 2
- 241000192019 Human endogenous retrovirus K Species 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102100022748 Wilms tumor protein Human genes 0.000 claims 2
- -1 c-Met Proteins 0.000 claims 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 102000036215 folic acid binding proteins Human genes 0.000 claims 2
- 108091011001 folic acid binding proteins Proteins 0.000 claims 2
- 102000056003 human IL15 Human genes 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000010445 mica Substances 0.000 claims 2
- 229910052618 mica group Inorganic materials 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100036008 CD48 antigen Human genes 0.000 claims 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims 1
- 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 101100445364 Mus musculus Eomes gene Proteins 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims 1
- 102100036840 T-box transcription factor TBX21 Human genes 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 101100445365 Xenopus laevis eomes gene Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000010212 intracellular staining Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229930192851 perforin Natural products 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000005909 tumor killing Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000389A JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666665P | 2018-05-03 | 2018-05-03 | |
| US62/666,665 | 2018-05-03 | ||
| US201862666965P | 2018-05-04 | 2018-05-04 | |
| US62/666,965 | 2018-05-04 | ||
| PCT/US2019/030721 WO2019213610A1 (en) | 2018-05-03 | 2019-05-03 | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Division JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522798A JP2021522798A (ja) | 2021-09-02 |
| JPWO2019213610A5 true JPWO2019213610A5 (enExample) | 2022-05-09 |
Family
ID=68386134
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561821A Pending JP2021522798A (ja) | 2018-05-03 | 2019-05-03 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000389A Pending JP2024045179A (ja) | 2018-05-03 | 2024-01-05 | 免疫チェックポイント遮断によりキメラ抗原受容体を発現するように操作されたナチュラルキラー細胞 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210230548A1 (enExample) |
| EP (1) | EP3788061A4 (enExample) |
| JP (2) | JP2021522798A (enExample) |
| KR (1) | KR20210005240A (enExample) |
| CN (1) | CN112292390A (enExample) |
| AU (1) | AU2019262218B2 (enExample) |
| BR (1) | BR112020022010A2 (enExample) |
| CA (1) | CA3099342A1 (enExample) |
| CO (1) | CO2020015168A2 (enExample) |
| MX (1) | MX2020011697A (enExample) |
| NZ (1) | NZ770183A (enExample) |
| SG (1) | SG11202010763VA (enExample) |
| WO (1) | WO2019213610A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG184733A1 (en) | 2007-09-18 | 2012-10-30 | Ligocyte Pharmaceuticals Inc | Method of conferring a protective immune response to norovirus |
| DK3299030T3 (da) | 2011-07-11 | 2022-09-05 | Takeda Vaccines Inc | Parenterale norovirus-vaccineformuleringer |
| CN110753555A (zh) * | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| AU2018364660B2 (en) * | 2017-11-09 | 2022-05-19 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible SH2-containing protein (CISH) gene |
| NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| CN113518826A (zh) * | 2018-05-16 | 2021-10-19 | 全国儿童医院研究所 | 利用cas9核糖核蛋白来产生敲除的原代和扩增的人nk细胞 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| MX2021011816A (es) * | 2019-03-29 | 2021-10-22 | Univ Texas | Metodos para produccion de celulas car-nk y uso de las mismas. |
| CA3140393A1 (en) * | 2019-06-04 | 2020-12-10 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
| US12195723B2 (en) * | 2019-11-08 | 2025-01-14 | The Broad Institute, Inc. | Engineered antigen presenting cells and uses thereof |
| CN115925976A (zh) * | 2019-11-21 | 2023-04-07 | 博生吉医药科技(苏州)有限公司 | Cd7-car-t细胞及其制备和应用 |
| CN115989034A (zh) * | 2019-11-27 | 2023-04-18 | 得克萨斯大学体系董事会 | Nk细胞的大规模组合car转导和crispr基因编辑 |
| CN114945377B (zh) * | 2019-11-27 | 2024-11-12 | 得克萨斯大学体系董事会 | Msc细胞的大规模组合car转导和crispr基因编辑 |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| WO2021142127A1 (en) * | 2020-01-08 | 2021-07-15 | Board Of Regents, The University Of Texas System | A method of engineering natural killer cells to target cd70-positive tumors |
| WO2021202581A1 (en) * | 2020-03-30 | 2021-10-07 | WUGEN, Inc. | Engineered immune cells for adoptive cell therapy |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| TW202237827A (zh) | 2020-12-03 | 2022-10-01 | 美商世紀治療股份有限公司 | 經基因工程改造之細胞及其用途 |
| EP4255453A4 (en) * | 2020-12-03 | 2025-03-26 | Nkarta, Inc. | Methods for manipulating immune cells for increased potency and persistence, as well as uses of engineered cells in immunotherapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| EP4262825A1 (en) | 2020-12-15 | 2023-10-25 | Universiteit Antwerpen | Cell-based therapeutics targeting cd70 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| US11473060B2 (en) | 2020-12-30 | 2022-10-18 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into NK cells |
| CN113005151A (zh) * | 2021-03-12 | 2021-06-22 | 广东药科大学 | 一种kdr-car-nk细胞的制备方法及其应用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| EP4341383A4 (en) * | 2021-05-20 | 2024-12-04 | Wuxi Biologics Ireland Limited | Genetically modified nk cells and uses thereof |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN113599395B (zh) * | 2021-09-22 | 2022-08-12 | 郑州源创吉因实业有限公司 | 含有nk细胞的治疗癌症的药物组合物 |
| MX2024003984A (es) * | 2021-10-01 | 2024-06-28 | Univ Texas | Celulas inmunitarias cargadas con anticuerpo y metodos para su uso en el tratamiento del cancer. |
| EP4416270A1 (en) * | 2021-10-15 | 2024-08-21 | Miltenyi Biotec B.V. & Co. KG | Method for the generation of genetically modified nk cells |
| EP4419541A4 (en) * | 2021-10-21 | 2025-12-17 | Univ Texas | METHOD FOR PRODUCING THERAPEUTIC IMMUNE CELLS WITH IMPROVED METABOLIC FITNESS AND COMPOSITIONS THEREOFUL |
| JP2024541074A (ja) * | 2021-11-04 | 2024-11-06 | サリオジェン セラピューティクス インコーポレイテッド | キメラ抗原受容体またはキメラ自己抗体受容体を有する免疫細胞 |
| UY40023A (es) | 2021-11-18 | 2023-05-31 | Janssen Biotech Inc | Métodos de cultivo celular sin alimentadora para la expansión de preparaciones de células destructoras naturales |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| CN114774364B (zh) * | 2022-04-26 | 2024-04-26 | 深圳市体内生物医药科技有限公司 | 一种嵌合抗原受体t细胞及其制备方法和应用 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| TW202432828A (zh) * | 2022-10-25 | 2024-08-16 | 日商武田藥品工業股份有限公司 | Ａｄｇｒｅ２嵌合受體ｎｋ細胞組成物及使用方法 |
| JP2025536042A (ja) * | 2022-11-10 | 2025-10-30 | オーエヌケイ セラピューティクス リミテッド | 免疫調節薬を用いた併用療法 |
| CN115947869B (zh) * | 2022-11-28 | 2023-12-12 | 广州佰芮慷生物科技有限公司 | 一种靶向人巨细胞病毒的嵌合抗原受体、car-nk细胞及用途 |
| CN115948344A (zh) * | 2023-02-10 | 2023-04-11 | 上海交通大学 | 嵌合抗原受体nk细胞、制备方法及其用途 |
| KR20250166262A (ko) * | 2023-03-24 | 2025-11-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 향상된 항종양 기억 반응을 갖는 조작된 자연 살해 세포 |
| KR20250167107A (ko) * | 2023-04-07 | 2025-11-28 | 엔카르타, 인크. | 자가면역 질환의 치료 방법 |
| CN116769722B (zh) * | 2023-07-04 | 2024-07-16 | 杭州荣谷生物科技有限公司 | 功能增强型car-nk细胞、其制备方法及其在免疫疗法中的应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) * | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487800B2 (en) * | 2010-09-08 | 2016-11-08 | Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus | Interleukin 15 as selectable marker for gene transfer in lymphocytes |
| EP3692794A1 (en) * | 2011-09-16 | 2020-08-12 | Baylor College of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| NO2794859T3 (enExample) * | 2011-12-22 | 2018-02-17 | ||
| IL257105B (en) * | 2015-07-31 | 2022-09-01 | Univ Minnesota | Modified cells and methods of therapy |
| JP2019505498A (ja) * | 2015-12-16 | 2019-02-28 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害 |
| EA201891614A1 (ru) * | 2016-01-11 | 2019-02-28 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Химерные белки и способы иммунотерапии |
| TW201740958A (zh) * | 2016-01-15 | 2017-12-01 | 依圖比克斯公司 | 用於t細胞免疫療法之方法及組合物 |
| MX2018014602A (es) * | 2016-05-27 | 2019-06-10 | Etubics Corp | Composiciones de vacunas neoepitopos y metodos de uso de las mismas. |
| GB2607227B (en) * | 2016-10-27 | 2023-05-10 | Intima Bioscience Inc | Viral methods of T cell therapy |
| CN110753555A (zh) * | 2017-04-19 | 2020-02-04 | 得克萨斯州大学系统董事会 | 表达工程化抗原受体的免疫细胞 |
| MX2021011816A (es) * | 2019-03-29 | 2021-10-22 | Univ Texas | Metodos para produccion de celulas car-nk y uso de las mismas. |
-
2019
- 2019-05-03 AU AU2019262218A patent/AU2019262218B2/en active Active
- 2019-05-03 CA CA3099342A patent/CA3099342A1/en active Pending
- 2019-05-03 SG SG11202010763VA patent/SG11202010763VA/en unknown
- 2019-05-03 EP EP19795874.7A patent/EP3788061A4/en active Pending
- 2019-05-03 KR KR1020207034764A patent/KR20210005240A/ko not_active Ceased
- 2019-05-03 WO PCT/US2019/030721 patent/WO2019213610A1/en not_active Ceased
- 2019-05-03 CN CN201980037453.2A patent/CN112292390A/zh active Pending
- 2019-05-03 JP JP2020561821A patent/JP2021522798A/ja active Pending
- 2019-05-03 MX MX2020011697A patent/MX2020011697A/es unknown
- 2019-05-03 BR BR112020022010-8A patent/BR112020022010A2/pt unknown
- 2019-05-03 US US17/050,775 patent/US20210230548A1/en active Pending
- 2019-05-03 NZ NZ770183A patent/NZ770183A/en unknown
-
2020
- 2020-12-02 CO CONC2020/0015168A patent/CO2020015168A2/es unknown
-
2024
- 2024-01-05 JP JP2024000389A patent/JP2024045179A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019213610A5 (enExample) | ||
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| Cerwenka et al. | Natural killer cell memory in infection, inflammation and cancer | |
| Thomson et al. | Double-negative regulatory T cells: non-conventional regulators | |
| Carter et al. | Type 1 and type 2: a fundamental dichotomy for all T-cell subsets | |
| JP6899333B2 (ja) | 汎用キラーｔ細胞 | |
| Kennedy et al. | Multiple roles for CD4+ T cells in anti‐tumor immune responses | |
| Brignone et al. | A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells | |
| Zhang et al. | B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion | |
| JP7000315B2 (ja) | 高結合活性ｈｐｖ ｔ細胞受容体 | |
| JP2016539929A5 (enExample) | ||
| Iwai et al. | An IFN-γ-IL-18 signaling loop accelerates memory CD8+ T cell proliferation | |
| JP2021500866A (ja) | 改変ｃａｒ−ｔ | |
| CN110404061B (zh) | 改进的t细胞治疗方法 | |
| TW202302842A (zh) | 培養細胞之方法 | |
| Letessier et al. | Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer | |
| WO2001038494A1 (en) | Method of proliferating natural killer cells | |
| JP3904374B2 (ja) | キラー活性を増強したリンパ球 | |
| US20240216426A1 (en) | Recombinant antigen presenting cells | |
| STOROZYNSKY et al. | Interleukin‐3 and granulocyte–macrophage colony‐stimulating factor enhance the generation and function of dendritic cells | |
| AU2016219379B2 (en) | Chlamydia-activated B cell platforms and methods thereof | |
| Kurosaki et al. | Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer | |
| Ni et al. | Blocking IL-10 signalling at the time of immunization does not increase unwanted side effects in mice | |
| Kim et al. | Comparison of the different anti-CD16 antibody clones in the activation and expansion of peripheral blood NK cells | |
| Werner et al. | DX5+ NKT cells display phenotypical and functional differences between spleen and liver as well as NK1. 1-Balb/c and NK1. 1+ C57Bl/6 mice |